KPIs & Operating Metrics(New)
Growth Metrics

Abbott Laboratories (ABT) Cash from Investing Activities (2016 - 2026)

Abbott Laboratories' Cash from Investing Activities history spans 18 years, with the latest figure at -$20.3 billion for Q1 2026.

  • On a quarterly basis, Cash from Investing Activities fell 4224.26% to -$20.3 billion in Q1 2026 year-over-year; TTM through Mar 2026 was -$22.3 billion, a 834.79% decrease, with the full-year FY2025 number at -$2.4 billion, down 3.59% from a year prior.
  • Cash from Investing Activities hit -$20.3 billion in Q1 2026 for Abbott Laboratories, down from -$913.0 million in the prior quarter.
  • Over the last five years, Cash from Investing Activities for ABT hit a ceiling of -$264.0 million in Q2 2022 and a floor of -$20.3 billion in Q1 2026.
  • Historically, Cash from Investing Activities has averaged -$1.8 billion across 5 years, with a median of -$582.0 million in 2025.
  • Biggest five-year swings in Cash from Investing Activities: soared 62.65% in 2024 and later tumbled 4224.26% in 2026.
  • Tracing ABT's Cash from Investing Activities over 5 years: stood at -$632.0 million in 2022, then tumbled by 30.38% to -$824.0 million in 2023, then decreased by 5.1% to -$866.0 million in 2024, then fell by 5.43% to -$913.0 million in 2025, then plummeted by 2126.07% to -$20.3 billion in 2026.
  • Business Quant data shows Cash from Investing Activities for ABT at -$20.3 billion in Q1 2026, -$913.0 million in Q4 2025, and -$457.0 million in Q3 2025.